מתןך אתר medicontext.co.il
Last Updated: 2001-08-08 15:58:11 EDT, Reuters Health
WESTPORT, CT (Reuters Health) – Gemifloxacin, a new quinolone antibiotic, is an effective and well-tolerated treatment for community-acquired pneumonia, according to a report in the July Journal of Antimicrobial Chemotherapy.
The initial empirical therapy for community-acquired pneumonia (CAP) must have a broad range of activity against the potentially antibiotic-resistant organisms increasingly encountered in this setting, the authors explain.
Dr. T. M. File, Jr., from Summa Health System, in Akron, Ohio and colleagues compared the safety and effectiveness of gemifloxacin with that of trovafloxacin in the treatment of CAP in 571 patients studied in Mexico, Spain, and the United States.
"At the time that this study was undertaken," the investigators write, "trovafloxacin was widely considered to be the most potent quinolone based on its in vitro potency versus community-acquired respiratory tract infection pathogens."
Two thirds of the patients received 7 days of treatment, the report indicates, though serious infection (as judged by the investigator) required 14 days of treatment in 36.9% of gemifloxacin patients and 33.8% of trovafloxacin patients.
Fewer than half the patients in either group had at least one pathogen identified at screening, the authors report. For the pathogen identified, gemifloxacin generally had lower minimum inhibitory concentrations than those of other antibacterial agents.
The two quinolones brought similar clinical responses in patients treated according to protocol, the results indicate, though gemifloxacin-treated patients fared better than did trovafloxacin-treated patients in the intent-to-treat analysis.
Bacteriologic responses at the end of therapy and at follow-up were also similar for the two groups, the researchers note, with eradication rates exceeding 87% in patients treated according to protocol.
Drug-related adverse events, most of them mild-to-moderate in severity, affected 20% of gemifloxacin-treated patients and 26% of trovafloxacin-treated patients, according to the report.
"Gemifloxacin 320 mg once daily was as effective as trovafloxacin 200 mg once daily for 7 or 14 days in the treatment of CAP," the authors conclude. "With regard to bacteriologic response, gemifloxacin was shown to be at least as effective as trovafloxacin, while for clinical response, gemifloxacin was significantly superior to trovafloxacin in the ITT population."
J Antimicrob Chemother 2001;48:67-74.